183 related articles for article (PubMed ID: 26449396)
1. California biomonitoring data: Comparison to NHANES and interpretation in a risk assessment context.
Aylward LL; Seiber JN; Hays SM
Regul Toxicol Pharmacol; 2015 Dec; 73(3):875-84. PubMed ID: 26449396
[TBL] [Abstract][Full Text] [Related]
2. A new method for generating distributions of biomonitoring equivalents to support exposure assessment and prioritization.
Phillips MB; Sobus JR; George BJ; Isaacs K; Conolly R; Tan YM
Regul Toxicol Pharmacol; 2014 Aug; 69(3):434-42. PubMed ID: 24845241
[TBL] [Abstract][Full Text] [Related]
3. Public health interpretation of trihalomethane blood levels in the United States: NHANES 1999-2004.
LaKind JS; Naiman DQ; Hays SM; Aylward LL; Blount BC
J Expo Sci Environ Epidemiol; 2010 May; 20(3):255-62. PubMed ID: 19550438
[TBL] [Abstract][Full Text] [Related]
4. Interpreting biomonitoring data for 2,4-dichlorophenoxyacetic acid: Update to Biomonitoring Equivalents and population biomonitoring data.
Aylward LL; Hays SM
Regul Toxicol Pharmacol; 2015 Dec; 73(3):765-9. PubMed ID: 26577196
[TBL] [Abstract][Full Text] [Related]
5. Deriving Biomonitoring Equivalents for selected E- and P-series glycol ethers for public health risk assessment.
Poet T; Ball N; Hays SM
Int J Hyg Environ Health; 2016 Jan; 219(1):88-100. PubMed ID: 26475513
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting interpretation of national biomonitoring data from multiple countries: BPA as a case study.
LaKind JS; Pollock T; Naiman DQ; Kim S; Nagasawa A; Clarke J
Environ Res; 2019 Jun; 173():318-329. PubMed ID: 30951958
[TBL] [Abstract][Full Text] [Related]
7. Screening of population level biomonitoring data from the Canadian Health Measures Survey in a risk-based context.
St-Amand A; Werry K; Aylward LL; Hays SM; Nong A
Toxicol Lett; 2014 Dec; 231(2):126-34. PubMed ID: 25455445
[TBL] [Abstract][Full Text] [Related]
8. Human biomonitoring as a pragmatic tool to support health risk management of chemicals--examples under the EU REACH programme.
Boogaard PJ; Hays SM; Aylward LL
Regul Toxicol Pharmacol; 2011 Feb; 59(1):125-32. PubMed ID: 20933039
[TBL] [Abstract][Full Text] [Related]
9. Biomonitoring equivalents: a screening approach for interpreting biomonitoring results from a public health risk perspective.
Hays SM; Becker RA; Leung HW; Aylward LL; Pyatt DW
Regul Toxicol Pharmacol; 2007 Feb; 47(1):96-109. PubMed ID: 17030369
[TBL] [Abstract][Full Text] [Related]
10. Environmental chemicals in people: challenges in interpreting biomonitoring information.
LaKind JS; Barraj L; Tran N; Aylward LL
J Environ Health; 2008 May; 70(9):61-4. PubMed ID: 18517157
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of NHANES biomonitoring data for volatile organic chemicals in blood: application of chemical-specific screening criteria.
Kirman CR; Aylward LL; Blount BC; Pyatt DW; Hays SM
J Expo Sci Environ Epidemiol; 2012; 22(1):24-34. PubMed ID: 21989501
[TBL] [Abstract][Full Text] [Related]
12. Chemical-specific screening criteria for interpretation of biomonitoring data for volatile organic compounds (VOCs)--application of steady-state PBPK model solutions.
Aylward LL; Kirman CR; Blount BC; Hays SM
Regul Toxicol Pharmacol; 2010 Oct; 58(1):33-44. PubMed ID: 20685286
[TBL] [Abstract][Full Text] [Related]
13. Biomonitoring Equivalents for benzene.
Hays SM; Pyatt DW; Kirman CR; Aylward LL
Regul Toxicol Pharmacol; 2012 Feb; 62(1):62-73. PubMed ID: 22178585
[TBL] [Abstract][Full Text] [Related]
14. Exposures to environmental phenols in Southern California firefighters and findings of elevated urinary benzophenone-3 levels.
Waldman JM; Gavin Q; Anderson M; Hoover S; Alvaran J; Ip HSS; Fenster L; Wu NT; Krowech G; Plummer L; Israel L; Das R; She J
Environ Int; 2016 Mar; 88():281-287. PubMed ID: 26821331
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of urinary speciated arsenic in NHANES: issues in interpretation in the context of potential inorganic arsenic exposure.
Aylward LL; Ramasamy S; Hays SM; Schoeny R; Kirman CR
Regul Toxicol Pharmacol; 2014 Jun; 69(1):49-54. PubMed ID: 24582650
[TBL] [Abstract][Full Text] [Related]
16. Biomonitoring Equivalents for molybdenum.
Hays SM; Macey K; Poddalgoda D; Lu M; Nong A; Aylward LL
Regul Toxicol Pharmacol; 2016 Jun; 77():223-9. PubMed ID: 26972837
[TBL] [Abstract][Full Text] [Related]
17. Identification and Prioritization of Relationships between Environmental Stressors and Adverse Human Health Impacts.
Bell SM; Edwards SW
Environ Health Perspect; 2015 Nov; 123(11):1193-9. PubMed ID: 25859761
[TBL] [Abstract][Full Text] [Related]
18. Human biomonitoring: state of the art.
Angerer J; Ewers U; Wilhelm M
Int J Hyg Environ Health; 2007 May; 210(3-4):201-28. PubMed ID: 17376741
[TBL] [Abstract][Full Text] [Related]
19. Temporal trends in bisphenol A exposure in the United States from 2003-2012 and factors associated with BPA exposure: Spot samples and urine dilution complicate data interpretation.
LaKind JS; Naiman DQ
Environ Res; 2015 Oct; 142():84-95. PubMed ID: 26121292
[TBL] [Abstract][Full Text] [Related]
20. Interpreting human biomonitoring data in a public health risk context using Biomonitoring Equivalents.
Hays SM; Aylward LL
Int J Hyg Environ Health; 2012 Feb; 215(2):145-8. PubMed ID: 22192580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
